Most linked-to pages

Showing below up to 50 results in range #51 to #100.

51. Gliadel: 13.9 months median survival; Combination with TMZ: Median survival ranges from 17 to 20.7 months‏‎ (3 links)
52. ICT-107 has demonstrated potential in extending progression-free and overall survival in GBM patients, especially in specific subgroups. Its ability to target multiple tumor-associated antigens may offer a broader immunogenic response.‏‎ (3 links)
53. Isotretinoin (Accutane)‏‎ (3 links)
54. Keppra‏‎ (3 links)
55. Keppra (Levetiracetam)‏‎ (3 links)
56. MN-166 (Ibudilast)‏‎ (3 links)
57. Melatonin‏‎ (3 links)
58. Methadone (D,L-methadone)‏‎ (3 links)
59. Not applicable; studies focusing on PFS-6 as a primary endpoint‏‎ (3 links)
60. Not reached at a median follow-up of 5.8 months‏‎ (3 links)
61. Not specified in the provided text‏‎ (3 links)
62. PFS-6 value was 53% in a restricted patient population with overexpression of PDGFR‏‎ (3 links)
63. Parthenolide‏‎ (3 links)
64. Procarbazine‏‎ (3 links)
65. Proton Beam Therapy (PBT)‏‎ (3 links)
66. Proton Pump Inhibitors (e.g., Lansoprazole, Nexium)‏‎ (3 links)
67. Proton Radiation Therapy‏‎ (3 links)
68. Resveratrol‏‎ (3 links)
69. Sativex‏‎ (3 links)
70. Sulforaphane‏‎ (3 links)
71. Temozolomide (TMZ)‏‎ (3 links)
72. VT-122‏‎ (3 links)
73. VT-122 (Propranolol and Etodolac combination)‏‎ (3 links)
74. Valproic Acid/Sodium Valproate (Depakote)‏‎ (3 links)
75. Vitamin D‏‎ (3 links)
76. Category:Repurposed Drugs‏‎ (3 links)
77. MediaWiki:Smw import foaf‏‎ (3 links)
78. Sodium R Lipoate and Hydroxycitrate (METABLOC)‏‎ (3 links)
79. Details on progression-free survival (PFS) improvement need further clarification; the trial primarily highlighted improvements in overall survival‏‎ (3 links)
80. The 2021 trial reported an increase in overall survival for glioblastoma patients treated with Sativex in combination with temozolomide compared to temozolomide alone‏‎ (3 links)
81. Standard Treatments‏‎ (3 links)
82. Data not specified‏‎ (3 links)
83. Phase II‏‎ (3 links)
84. Research It Yourself‏‎ (3 links)
85. 14-16 months with standard treatment.‏‎ (2 links)
86. 16 months (control group in EF-14 Trial)‏‎ (2 links)
87. 17% in the study of patients with tumors recurring after radiation; 38% in a study using PCV for tumors recurrent after radiation (and for some after prior chemotherapy); 13% in a study with PCV after Temodar failure‏‎ (2 links)
88. 20.9 months (Optune plus temozolomide, final EF-14 analysis)‏‎ (2 links)
89. 3 (awaiting research)‏‎ (2 links)
90. 5.6 months reported in recent studies using fractionated sessions with Gamma Knife ICON.‏‎ (2 links)
91. 8.0 months mOS observed in phase 2 trial for patients receiving treatment dose of 30 mg/m2/day‏‎ (2 links)
92. ABT-414‏‎ (2 links)
93. AVAglio trial: 16.8 months; RTOG trial: 15.7 months‏‎ (2 links)
94. Accutane‏‎ (2 links)
95. Agenus Prophage (Heat-Shock Protein Peptide Complex-96) Vaccine‏‎ (2 links)
96. Anlotinib‏‎ (2 links)
97. Anti-CMV Dendritic Cell Vaccine‏‎ (2 links)
98. Based on available data, potentially highly useful in specific dosing schedules‏‎ (2 links)
99. Beta-blockers (especially propranolol) and the role of the sympathetic‏‎ (2 links)
100. Celebrex‏‎ (2 links)